新型冠状病毒变异株对新型冠状病毒疾病诊治及防疫的影响分析

doi:10.3969/j.issn.2095-378X.2021.03.013

外科研究与新技术 ›› 2021, Vol. 10 ›› Issue (3): 203-208.doi: 10.3969/j.issn.2095-378X.2021.03.013

新型冠状病毒变异株对新型冠状病毒疾病诊治及防疫的影响分析

张珂¹, 沈洁¹ 综述, 胡丽华² 审校

1.上海奥普生物医药股份有限公司,上海 201201;
2.同济大学附属同济医院《外科研究与新技术》编辑部,上海 200065

收稿日期:2021-08-11 出版日期:2021-09-28 发布日期:2022-08-22
通讯作者: 胡丽华,电子信箱：hlh763@126.com
作者简介:张珂（1983—）,男,博士,工程师,从事医疗器械研发工作
基金资助:
上海即时检测医学工程技术研究中心（18DZ2250700）; 上海医学即时检验产业技术创新战略联盟（11DZ0512200）; 2017上海领军人才项目-李福刚（042）

Impacts of SARS-CoV-2 variants on diagnosis, treatment, and control of COVID-19

ZHANG Ke¹, SHEN Jie¹, HU Lihua²

1. Shanghai Upper Bio-tech Pharma Co., Ltd., Shanghai 201201, China;
2. Editorial Department of Surgical Research and New Technique, Tongji Hospital Affiliated to Tongji University, Shanghai 200065, China

Received:2021-08-11 Online:2021-09-28 Published:2022-08-22

摘要/Abstract

摘要： 新型冠状病毒在全球多国陆续演变出多个变异株,传播力和危害性逐步累积增强。目前Delta变异株已侵入我国,造成了严重的危害。新冠病毒的持续变异,已成为全球关注的焦点。本文汇总分析各典型变异株的研究数据,从生物学角度探讨变异株对病原体检测、治疗、疫苗等方面的影响,以及病毒持续变异对防疫工作造成的冲击和应对策略。

关键词: 新型冠状病毒, 变异株, 突变, 诊断, 治疗, 疫苗, 疫情防控

Abstract: Multiple variants of SARS-CoV-2 have appeared in many countries across the world and resulted in the gradual enhancement of viral transmission and infection. Recently, Delta variant invaded China and caused serious consequences. The continuous mutation of SARS-CoV-2 is turning into a critical topic of global pandemic control. By summarizing the studies of typical variants, this article analyzed the impacts of SARS-CoV-2 variants on diagnosis, treatment, and vaccination from the perspective of biology, and discussed the strategies on how to tackle the challenge of the continuous mutation.

Key words: SARS-CoV-2, Variant, Mutation, Diagnosis, Treatment, Vaccine, Pandemic control

中图分类号:

R183.3

张珂, 沈洁, 胡丽华. 新型冠状病毒变异株对新型冠状病毒疾病诊治及防疫的影响分析[J]. 外科研究与新技术, 2021, 10(3): 203-208.

ZHANG Ke, SHEN Jie, HU Lihua. Impacts of SARS-CoV-2 variants on diagnosis, treatment, and control of COVID-19[J]. Surgical Research and New Technique, 2021, 10(3): 203-208.

参考文献

[1] Kim D, Lee J Y, Yang J S, et al.The architecture of SARS-CoV-2 transcriptome[J]. Cell, 2020,181(4):914-921.
[2] Ferron F, Subissi L, De Morais A T S, et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus rna[J]. PNAS, 2018,115(2):E162-E171.
[3] Gerhard W, Mozdzanowska K, Zharikova D.Prospects for universal influenza virus vaccine[J]. Emerg Infect Dis, 2006,12(4):569-574.
[4] Laffeber C, Koning K D, Kanaar R, et al.Experimental evidence for enhanced receptor binding by rapidly spreading SARS-CoV-2 variants[J]. J Mol Biol, 2021,433(15):167058.
[5] Xie X, Liu Y, Liu J, et al.Neutralization of SARS-CoV-2 spike 69/70 deletion, e484k and n501y variants by bnt162b2 vaccine-elicited sera[J]. Nat Med, 2021,27(4):620-621.
[6] Collier D A, De M A, Ferreira I A, et al.Sensitivity of SARS-CoV-2 b.1.1.7 to mrna vaccine-elicited antibodies[J]. Nature, 2021,593(7857):136-141.
[7] Campbell F, Archer B, Laurenson-Schafer H, et al.Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021[J]. Eurosurveillance, 2021,26(24):1-6.
[8] Deng X, Garcia-Knight M A, Khalid M M, et al. Transmission, infectivity, and neutralization of a spike l452r SARS-CoV-2 variant[J]. Cell, 2021,184(13):3426-3437.
[9] Zhou B, Thao T T N, Hoffmann D, et al. SARS-CoV-2 spike d614g change enhances replication and transmission[J]. Nature, 2021,592(7852):122-127.
[10] 杨梅,张晓天,刘秀敏,等.新型冠状病毒检测方法的应用现状[J]. 中国实验诊断学, 2020,24(7):1204-1207.
[11] Karim S, Oliveira T D.New SARS-CoV-2 variants-clinical, public health, and vaccine implications[J]. New Engl J Med,2021,384(19):1866-1868.
[12] Sadoff J, Gray G, Vandebosch A, et al.Safety and efficacy of single-dose Ad26. Cov2. S vaccine against COVID-19[J]. New Engl J Med, 2021,384(23):2187-2201.
[13] Lopez Bernal J, Andrews N, Gower C, et al.Effectiveness of COVID-19 vaccines against the b.1.617.2 (delta) variant[J]. New Engl J Med, 2021,385(7):585-594.
[14] Emary K R, Golubchik T, Aley P K, et al.Efficacy of chadox1 nCOV-19 (azd1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (b.1.1.7): An exploratory analysis of a randomised controlled trial[J]. The Lancet, 2021,397(10282):1351-1362.
[15] Wang P, Nair M S, Liu L, et al.Antibody resistance of SARS-CoV-2 variants b.1.351 and b.1.1.7[J]. Nature, 2021,593(7857):130-135.
[16] Edara V V, Norwood C, Floyd K, et al.Infection-and vaccine-induced antibody binding and neutralization of the b.1.351 SARS-CoV-2 variant[J]. Cell Host Microbe, 2021,29(4):516-521.
[17] Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant b.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines[J]. Cell Host Microbe, 2021,29(4):529-539.
[18] Hoffmann M, Arora P, Groß R, et al.SARS-CoV-2 variants b.1.351 and p.1 escape from neutralizing antibodies[J]. Cell, 2021,184(9):2384-2393.
[19] Kuzmina A, Khalaila Y, Voloshin O, et al.SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera[J]. Cell Host Microbe, 2021,29(4):522-528.
[20] 穆鑫,赵颖,张兰,等.我国治疗新冠肺炎药物临床研究现状浅析[J]. 中国临床药理学与治疗学, 2020,25(8):869-877.
[21] Weinreich D M, Sivapalasingam S, Norton T, et al.Regn-cov2, a neutralizing antibody cocktail, in outpatients with COVID-19[J]. New Engl J Med, 2021,384(3):238-251.
[22] Hansen J, Baum A, Pascal K E, et al.Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail[J]. Science, 2020,369(6506):1010-1014.
[23] Kidd M, Richter A, Best A, et al.S-variant SARS-CoV-2 lineage b1. 1.7 is associated with significantly higher viral load in samples tested by taqpath polymerase chain reaction[J]. J Infect Dis, 2021,223(10):1666-1670.
[24] Rockx B, Kuiken T, Herfst S, et al.Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model[J]. Science, 2020,368(6494):1012-1015.
[25] Vogel G.Mixing vaccines may boost immune responses[J]. Science, 2021,372(6547):1138.
[26] Andersen K G, Rambaut A, Lipkin W I, et al.The proximal origin of SARS-CoV-2[J]. Nat Med, 2020,26(4):450-452.
[27] Zhou P, Yang X L, Wang X G, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020,579(7798):270-273.
[28] Li W.Bats are natural reservoirs of SARS-like coronaviruses[J]. Science, 2005,310(5748):676-679.
[29] Azhar E I, El-Kafrawy S A, Farraj S A, et al. Evidence for camel-to-human transmission of MERS coronavirus[J]. New Engl J Med, 2014,370(26):2499-2505.
[30] Shi J, Wen Z, Zhong G, et al.Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2[J]. Science, 2020,368(6494):1016-1020.

新型冠状病毒变异株对新型冠状病毒疾病诊治及防疫的影响分析

Impacts of SARS-CoV-2 variants on diagnosis, treatment, and control of COVID-19

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王茜, 朱旭友, 张灏杨, 孙和国, 李佳, 高青云, 易祥华. 皮肤淋巴上皮瘤样癌1例及文献复习[J]. 外科研究与新技术, 2022, 11(1): 51-55.
[2]	张晓林, 金玲. 外耳道胆脂瘤36例临床分析[J]. 外科研究与新技术, 2021, 10(4): 273-276.
[3]	邹专, 和文宝, 李兵, 赵有光, 周海超, 杨云峰. 经皮复位空心螺钉固定治疗第五跖骨基底部撕脱性骨折[J]. 外科研究与新技术, 2021, 10(2): 97-100.
[4]	李晨光, 葛均波. 介入手术机器人系统在经皮冠状动脉介入治疗中的临床应用探讨[J]. 外科研究与新技术, 2021, 10(1): 1-3.
[5]	刘南斌, 许艳, 魏玉华, 刘中砚, 陈泉宁, 施宝民. 急性坏疽性胆囊炎39例诊疗分析[J]. 外科研究与新技术, 2021, 10(1): 37-41.
[6]	王春球, 李玉勤, 孟宪国, 陈应超, 钟雪瑜. 输尿管镜下气压弹道碎石术治疗输尿管中下段结石并发感染患者的临床效果[J]. 外科研究与新技术, 2020, 9(4): 234-236.
[7]	周彭玲, 周贤军, 白帆. 经阴道超声诊断剖宫产术后子宫切口憩室的临床效果[J]. 外科研究与新技术, 2020, 9(4): 267-270.
[8]	刘南斌, 吴刚, 卞崔冬. 12例TVT‐O术后并发吊带侵袭膀胱的诊疗分析[J]. 外科研究与新技术, 2020, 9(3): 154-157.
[9]	许艳, 刘南斌. 黄色肉芽肿性胆囊炎的临床困境[J]. 外科研究与新技术, 2020, 9(3): 197-200.
[10]	姚英, 钱莹珊, 汤爱玲. 新型冠状病毒肺炎疫情期间手术室在清单式管理下的安全防控护理质量[J]. 外科研究与新技术, 2020, 9(2): 134-138.
[11]	黄启豪. 自动痔疮套扎术联合地奥司明在混合痔临床治疗中的应用[J]. 外科研究与新技术, 2020, 9(1): 35-38.
[12]	谷丽, 于蕾, 张艺骞, 王新立. 马德龙病1例[J]. 外科研究与新技术, 2020, 9(1): 59-62.
[13]	朱旭友, 施娟红, 易祥华, 张子强, 郑少强, 张龙, 刘玉婷, 曾郁, 韩洪秀, 方霞. 经支气管冷冻肺活检诊断间质性肺疾病的价值分析[J]. 外科研究与新技术, 2019, 8(4): 248-252.
[14]	王永亮, 柴辉, 赵宏卿, 王怀锦, 褚瑞军, 郭思亮, 翟耀君. 他莫昔芬与阿那曲唑乳腺癌内分泌治疗对于骨代谢水平的影响[J]. 外科研究与新技术, 2019, 8(4): 262-264.
[15]	叶思丹, 陈园, 熊霞. 在康复治疗的不同阶段对距腓前韧带损伤患者进行运动医学超声检查的临床意义[J]. 外科研究与新技术, 2019, 8(4): 269-272.